Filing Details
- Accession Number:
- 0001209191-19-023072
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-03 16:12:33
- Reporting Period:
- 2019-04-01
- Accepted Time:
- 2019-04-03 16:12:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1439222 | Agios Pharmaceuticals Inc | AGIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1608601 | Christopher Bowden | C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-04-01 | 10,000 | $35.16 | 17,238 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-04-01 | 5,854 | $66.03 | 11,384 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-04-01 | 2,546 | $66.85 | 8,838 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-04-01 | 1,500 | $68.09 | 7,338 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-04-01 | 100 | $68.72 | 7,238 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2019-04-01 | 10,000 | $0.00 | 10,000 | $35.16 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 71,000 | 2024-05-30 | No | 4 | M | Direct |
Footnotes
- This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $65.50 to $66.49. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $66.50 to $67.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $67.71 to $68.55. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
